GlassScriptPhysician profile
Lorin Michael Graef
NPI 1750343703
$4,352.79
in general payments reported to CMS, 2019-2025
25 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $209 · 2021: $329 · 2022: $469 · 2023: $826 · 2024: $813 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,318.76 | 2021-2025 | |
| Lilly USA, LLC | $522.77 | 2022-2025 | Kisunla, Amyvid |
| Eisai INC. | $419.21 | 2023-2025 | |
| Argenx US, INC. | $351.99 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $260.87 | 2019-2024 | Apokyn |
| Otsuka America Pharmaceutical, INC. | $259.92 | 2024-2025 | Rexulti |
| Allergan, INC. | $249.51 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $160.64 | 2022-2025 | Xeomin, Inbrija |
| Biohaven Pharmaceuticals, INC. | $157.45 | 2021 | |
| Biogen, INC. | $121.80 | 2021-2025 | Leqembi |
| Pfizer INC. | $65.83 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $64.30 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $54.69 | 2023-2024 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $54.46 | 2022 | |
| Neurocrine Biosciences, INC. | $39.79 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $36.40 | 2022-2025 | Crexont |
| Novartis Pharmaceuticals Corporation | $31.55 | 2021 | |
| Lundbeck LLC | $30.09 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.56 | 2025 | Keveyis |
| Abbott Laboratories | $23.75 | 2025 | Infinity |
| Brainsway USA INC | $22.66 | 2022 | |
| Corium, LLC | $21.26 | 2022 | |
| Insightec,INC | $20.78 | 2025 | Exablate |
| Cala Health, INC. | $20.77 | 2023 | Cala Trio |
| Revance Therapeutics, INC. | $18.98 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorin Graef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.